John Connelly

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Antonio Martín‐Bastida, Roberta J. Ward, Rexford D. Newbould et al. · Scientific Reports · 2017 · 368 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

Eric C. Polley, Mark W. Kunkel, David M. Evans et al. · JNCI Journal of the National Cancer Institute · 2016 · 173 citations · Full text

Medicine, Oncology, Pharmacology +17

The Oral Iron Chelator Deferiprone Protects against Iron Overload–Induced Retinal Degeneration

Majda Hadziahmetovic, Ying Song, Natalie Wolkow et al. · Investigative Ophthalmology & Visual Science · 2010 · 118 citations · Full text

Medicine, Ophthalmology, Pharmacology +17

Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]

Andrew G. Jobson, G.T. Lountos, Philip L. Lorenzi et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 94 citations · Full text

Medicine, Oncology, Pharmacology +15

Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets

Julia Krushkal, Thomas Silvers, William C. Reinhold et al. · Clinical Epigenetics · 2020 · 87 citations · Full text

Life Sciences, Molecular Biology, Oncology +17